Stem cell therapy describes different medical approaches, each with its own purpose, evidence and risks. MPGCARE helps coordinate enquiries with the appropriate team at partner Medical Park and Liv Hospital hospitals in Türkiye. The hospital reviews the diagnosis and proposed approach before confirming suitability and services.
Blood-forming stem cell transplantation is used for selected blood and immune-system conditions. It differs from regenerative cell procedures proposed for joints, wounds or neurological disease. An enquiry about one approach does not establish eligibility for another. The specialist should explain the exact procedure and its evidence for your diagnosis.

Conditions and the type of specialist review

This broad guide includes established transplant pathways, highly selected specialist indications and investigational enquiries. It is not an exhaustive medical indication list or confirmation that each intervention is available. The cell type and protocol must match the diagnosis; the specialist confirms the evidence level for the exact procedure.

What does stem cell therapy mean?
A clear proposal identifies the cells, source, processing, route of administration and medical purpose. Laboratory preparation and a clinical treatment are different steps; cell quality alone does not show that an intervention will improve a particular disease.
Ask the receiving team to name the proposed treatment precisely. Terms such as regenerative medicine or cellular therapy should be accompanied by an explanation of the actual procedure, available evidence and uncertainties.

What is the difference between autologous and allogeneic treatment?
Autologous means cells come from the patient; allogeneic means they come from a donor. These words describe the source, not a guarantee of safety or benefit. Blood-forming transplantation has its own matching and treatment pathway.
Ask why that source is appropriate, what collection or donor assessment is required and how it changes risk and follow-up. The transplant team determines matching requirements where applicable.

Is the proposed procedure established treatment or research?
Some stem cell applications are established for specific conditions; many others remain investigational. Ask whether the proposed procedure is routine treatment or part of a properly supervised research study. Registration of a study alone does not prove benefit.
For research, request the protocol, sponsor, ethics review, inclusion criteria and consent information. Ask about alternatives, withdrawal, costs and who manages complications. Do not interpret a laboratory certificate as approval for every clinical use.

How will the team decide whether I am suitable?
The hospital reviews your diagnosis, severity, previous treatments, general health and the question you want answered. Ask what additional tests are needed before a recommendation can be made. Tests differ between blood-forming transplantation and regenerative enquiries.
Agree on measurable goals and when outcomes will be reviewed. A universal recovery promise or an identical infusion for many unrelated conditions should prompt further explanation and an independent opinion.

What happens during blood-forming stem cell transplantation?
When appropriate, the hematology/transplant team explains cell collection or donor arrangements, preparative treatment, infusion and recovery monitoring. Engraftment means the transplanted cells begin producing blood cells. This is a specialist pathway rather than a simple wellness infusion.
Ask about admission, nearby accommodation after discharge, a caregiver and the expected monitoring schedule. The plan depends on transplant type and the underlying disease.

What risks should the patient and family understand?
Risks depend on the product and procedure. Blood-forming transplantation can involve infection, bleeding and treatment-related organ problems; donor transplants may cause graft-versus-host disease. Other cell procedures have different, sometimes incompletely understood risks.
Request a written discussion of your individual risks and the hospital’s plan for urgent problems. Using your own cells does not eliminate risk. Obtain a contact and instructions before treatment, not only after discharge.

What follow-up is needed, and should existing treatment continue?
Ask which examinations, blood tests or outcome measures are needed and who reviews them. After blood-forming transplantation, recovery and immune monitoring may continue well beyond the hospital stay. Follow the team’s medicines and infection-prevention instructions.
Do not stop existing treatment because you have requested a cellular consultation. Agree on coordination with your usual doctor and obtain a written follow-up plan before returning home.

Which records should we prepare?
Prepare the exact diagnosis, age, current prescriptions, allergies and previous treatment history. Include relevant pathology, genetic results, imaging, laboratory results and discharge reports. A blood-cancer enquiry requires different records from a joint or wound enquiry.
State the proposed procedure if another provider has already recommended one. Share records through the agreed secure channel and ask which documents need translation.

How are costs, consent and travel planned?
After review, request a written proposal identifying the procedure, cell-related arrangements, hospital care, tests and follow-up. Clarify what happens if you are found unsuitable, treatment is postponed or complications require additional care.
Finalize travel after clinical acceptance and discuss return clearance with the treating team. Duration varies; blood-forming transplantation may require a prolonged stay and continuing specialist follow-up.

Are patient transfers free?
MPGCARE offers free Sarp–Trabzon transfers for patients arriving by land and free airport-to-hospital transfers for patients arriving by air. Coordinate arrival, destination and accompanying person with our team.
These transfers do not replace medically supervised transport. The clinical team should advise on travel if you are unwell or recovering from transplantation.

How do we request a specialist assessment?
Tell MPGCARE your diagnosis, available records and the purpose of your enquiry. We help coordinate review by a suitable partner team. The hospital confirms the applicable treatment or research pathway and explains the next steps; no procedure is guaranteed before assessment.

How do we confirm evidence and eligibility for our diagnosis?
Before proceeding, ask for the exact indication, cell product, clinical evidence and applicable authorization. A condition being researched does not establish that a commercial procedure is effective or available for your case. The hospital should distinguish standard care, highly selected transplant practice and investigational cell interventions.

Will the treatment cure the disease?
No outcome can be promised before an individual review. The team should explain the intended goal: disease control, recovery of blood formation or a research outcome. Ask how benefit is measured, when it will be reviewed and what happens if the goal is not reached.

Does the patient need a donor?
That depends on the exact procedure. Autologous treatment uses the patient’s cells; an allogeneic pathway requires donor assessment. Ask whether a donor is needed, how suitability is checked and how donor availability affects timing. A relative is not automatically an appropriate donor.

How are cells collected and administered? Is it painful?
The collection source and delivery route differ by treatment. Ask whether collection involves blood, marrow or another tissue; what anesthesia or pain relief is planned; and whether admission is required. The team should describe both collection and administration, rather than only the infusion.

How long will we stay, and can a family member accompany the patient?
The hospital should provide an initial plan after assessment, including inpatient care, accommodation near the center and early follow-up. Blood-forming transplantation and other procedures have different timelines. Ask about caregiver duties, visiting rules and whether the companion’s accommodation is included.

Can children receive treatment?
Age alone does not establish eligibility. A pediatric specialist must confirm the diagnosis, indication, risks and appropriate center. Families should receive an age-appropriate explanation and the hospital’s consent and support arrangements. Do not assume that an adult protocol can be applied to a child.

When can we travel home and who helps afterwards?
Return travel requires clinical clearance. Obtain the discharge report, medicine list, local follow-up requirements and an emergency contact. Agree how your doctor at home will receive updates and who reviews new symptoms or delayed results. Transfer coordination and ongoing medical care are separate responsibilities.

What should relatives do if the patient becomes unwell?
Follow the written urgent-care plan from the treating team. Fever, breathing difficulty, collapse or a rapidly worsening condition after a procedure needs prompt medical attention. Do not wait for a routine online appointment. Keep the treatment details and prescriptions available for local clinicians.

What happens if the specialist does not recommend the procedure?
Ask for the reason and the recommended alternatives or further assessment. A decision against a cell intervention can reflect diagnosis, stage, health risks or insufficient evidence. MPGCARE can help coordinate the next appropriate specialty consultation; an enquiry does not commit you to a procedure.

Medical information sources: NCI: blood-forming transplantation · NHS: transplant indications · ISSCR: patient guide · NHS: transplant recovery

EBMT — MS & HSCT